Business
Tetra Bio-Pharma Provides Update on Recent Milestones
Tetra Bio-Pharma Provides Update on Recent Milestones.
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"Plenitude Trial initiatedTetra completes clinical study assessing the metabolism profile of cannabinoids in humansAchieved development of ARDS-003 sterile injectable nano-emulsion for human useOTTAWA, ON / ACCESSWIRE / November 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today provided an update on its ARDS-003, CAUMZ™, PPP-003 (ophthalmic) and QIXLEEF™ programs.At its June 2020 Annual General Meeting (AGM), Tetra announced it was planning to complete the following milestones in 2020:Complete mapping of cannabinoid metabolites;Initiate Reborn© trial with CAUMZ™;Finalize commercial readiness - manufacturing scale-up for CAUMZ™;Complete IND-enabling nonclinical safety studies of its COVID-19 drug, ARDS-003;Initiate the Phase 1 study for ARDS-003;Initiate the Phase 2 study for ARDS-003;QIXLEEF™ drug supply and study initiation.Milestone - Complete mapping of human cannabinoids and metabolites:Tetra completed this especially important milestone during Q3 2020. This milestone has a major impact on both QIXLEEF™, CAUMZ™. Knowledge from completing this milestone will also figure prominently in any other THC- or CBD-based product that Tetra will develop, as it defines the metabolite profile of cannabinoids administered by inhalation. It demonstrated the ability of Tetra's inhalation technology to quickly deliver significantly higher levels of these cannabinoids to the brain and showed a profile favoring liver safety.Milestone - Initiate Reborn© trial:At its AGM, Tetra shared the rationale for making Reborn© the priority over Serenity©. Reborn© is designed to be able to demonstrate the ability of inhaled cannabinoids to reduce the use of opioids in patients suffering from breakthrough pain, which represents a major scientific milestone. Tetra has shown that inhalation achieves very rapidly maximum plasma concentrations of THC in humans. Furthermore, this peak level in the blood is associated with the peak of the pharmacodynamic effect. Tetra has hypothesized that achieving this pharmacodynamic effect within 5 to 10 minutes in patients will provide significant relief through a dissociation mechanism. Consequently, by increasing a patient's tol...